Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05747924 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy, sponsored by Avidity Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 17
- Study locations
NCT05747924: Active Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy, sponsored by Avidity Biosciences.
NCT05747924 is a Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy that is active but no longer recruiting, run by Avidity Biosciences. The registered enrollment target is 90 participants, below the 1,883-participant average among 3 other FSHD trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05747924, a Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy, is active but no longer recruiting, sponsored by Avidity Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AOC 1020
Study Locations (17)
California
- University of California Los Angeles - Los Angeles
- Stanford University - Palo Alto
- University of California San Diego - San Diego
Other
- University College London - London
- University of Sheffield - Sheffield
Colorado
- University of Colorado - Denver
Florida
- University of Florida - Gainesville
Georgia
- Rare Disease Research - Atlanta
Kansas
- Kansas University Medical Center - Kansas City
New York
- University of Rochester Medical Center - Rochester
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What the registry record for NCT05747924 still lists
NCT05747924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,883-participant average among 3 other FSHD trials with a reported enrollment target (95% lower).
The record links to 10 conditions, with FSHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05747924 lists 17 locations in 14 states (California, Other, Colorado).
Frequently Asked Questions
What is clinical trial NCT05747924 about?
NCT05747924 is a clinical study titled "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)". A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
What is the current status of trial NCT05747924?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2023-04-04. Estimated completion is 2027-04.
What conditions does trial NCT05747924 study?
This clinical trial studies the following conditions: FSHD, Fascioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy Type 1.
What interventions are being tested in trial NCT05747924?
The interventions under investigation include: Placebo (DRUG), AOC 1020 (DRUG).
Who is sponsoring clinical trial NCT05747924?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05747924 being conducted?
This trial has 17 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FSHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI